• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

DexCom beats Street with Q4 earnings

March 1, 2017 By Sarah Faulkner

DexCom beats Street with Q4 earningsShares in DexCom Inc. (NSDQ:DXCM) rose today after the medical device maker met expectations on Wall Street with its 4th quarter results.

The San Diego-based company posted a loss of -$7.4 million, or -9¢ per share, on sales of $171.2 million for the 3 months ended Dec. 31, for bottom-line loss of -593.3% on sales growth of 30.9% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -9¢, a penny ahead of consensus on The Street, where analysts were looking for sales of $167.3 million.

“2016 was a strong year for DexCom,” president & CEO Kevin Sayer said in prepared remarks. “The company not only generated record revenue but also achieved a number of important milestones, including the first ever non-adjunctive indication from the FDA. We look forward to continued global growth in 2017 and beyond.”

DexCom said it expects to bring in sales of $710 million to $740 million for the full year of 2017.

DXCM shares were trading at $82.07 apiece today in morning activity, up 5.1%.

The company’s G5 Mobile device is the only FDA-approved glucose measurement system that is cleared for therapeutic decision-making. Earlier this year, DexCom scored another win when the Centers for Medicare & Medicaid classified therapeutic continuous glucose monitors as durable medical equipment under Medicare Part B.

The G5 Mobile is the only CGM system that falls under the therapeutic classification, according to the company, since patients can make treatment decisions using the device.

Leerink Partners analyst Danielle Antalffy said in a report that DexCom is poised to grow in the coming year, thanks to the CMS coverage decision and the FDA indication approval.

“At the very least, we believe recently-announced CMS coverage makes DXCM’s 2017 sales growth guidance easily achievable, and at best likely beatable,” Antalffy wrote. “And with a plethora of incremental growth drivers, including an expected G6 launch in 2018 with yet again a best-in-class MARD and ongoing international expansion, DXCM is well-positioned to drive sustainably strong double-digit growth – likely 20%+ and accelerating as new products launch – longer term.”

Filed Under: Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: DexCom Inc.

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS